ISSN: 2459-1777 | E-ISSN 2587-0394
Volume : Issue : Year : 2023
Beyoglu Eye Journal Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion [Beyoglu Eye J]
Beyoglu Eye J. 2023; 8(1): 21-25 | DOI: 10.14744/bej.2023.42243

Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion

Seda Gürakar Özçift1, Erdinc Aydin2, Emine Deniz Egrilmez1, Feray Koc2, Erdem Eriş3
1Department of Opthalmology, Izmir Katip Celebi University, Atatürk Training and Research Hospital, İzmir, Türkiye
2Department of Opthalmology, Izmir Katip Celebi University, İzmir, Türkiye
3Department of Opthalmology, Health Sciences University Izmir Dr. Behcet Uz Child Diseases and Surgery Training and Research Hospital, İzmir, Türkiye

OBJECTIVES: This study aimed to compare the effects of dexamethasone (DEX) implants and ranibizumab (RAN) injec-tions in younger patients with macular edema due to branch retinal vein occlusion (RVO) in a 6-month follow-up.
METHODS: The treatment-naive patients with macular edema secondary to branch RVO were included retrospectively. Med-ical records of patients who were treated with intravitreal RAN or DEX implant were evaluated before and at the 1st, 3rd, and 6th months after the injection. Primary outcome measures were the change in best-corrected visual acuity (BCVA) and central retinal thickness. The level of statistical significance was set at 0.05/3=0.016, according to the Bonferroni correction.
RESULTS: Thirty-nine eyes of 39 patients were included in the study. The mean age of the study population was 53.82±5.08 years. Median BCVA in the DEX group (n=23) at baseline, 1st, 3rd, and 6th month was 1.1, 0.80 (p=0.002), 0.70 (p=0.003), and 1 (p=0.018) logarithm of the minimum angle of resolution (log-MAR), respectively (p<0.05). Median BCVA in the RAN group (n=16) at baseline, 1st, 3rd, and 6th months was 0.90, 0.61, 0.52, and 0.46 logMAR, respectively (p<0.016 for all comparisons). Median central macular thickness (CMT) in the DEX group at baseline, 1st, 3rd, and 6th months was 515, 260, 248, and 367 μm, respectively (p<0.016 for all comparisons). Median CMT in the RAN group at baseline, 1st, 3rd, and 6th months was 432.5 (p<0.016), 275 (p<0.016), 246 (p<0.016), and 338 (p=0.148) μm.
DISCUSSION AND CONCLUSION: There is no significant difference in treatment efficacies in both visual and anatomical outcomes at the end of the 6th month. However, RAN can be considered the first choice in younger patients with macular edema secondary to branch RVO because of the lower side effect profile.

Keywords: Branch retinal vein occlusion, dexamethasone implant, macular edema, ranibizumab.

Seda Gürakar Özçift, Erdinc Aydin, Emine Deniz Egrilmez, Feray Koc, Erdem Eriş. Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion. Beyoglu Eye J. 2023; 8(1): 21-25

Corresponding Author: Seda Gürakar Özçift, Türkiye
Manuscript Language: English
LookUs & Online Makale